Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
8 papers
Recent·Most cited
W. Liu, J.-Y. Lu, Y.-J. Wang, X.-x. Xu, Y.-C. Chen, S.-X. Yu, X.-W. Xiang, X.-Z. Chen, Y. Jiu, H. Gao, M. Sheng, Z.-J. Chen, X. Hu, D. Li, P. Maiuri, , Y.-J. Liu
This study shows vaccinia virus induces EMT-like changes and RhoA-mediated mesenchymal migration in epithelial cells, facilitating viral spread.
bioRxiv · Feb 4, 2023Cell Biology
L. Sun, W. Zhan, X. Tian, X. Zhang, S. Xing, W. Song, Q. Liu, A. Hao, Y. Hu, M. Zhang, Z. Chen, T. Ying, F. Lan
This paper identifies a potent SARS-CoV-2 antibody, 553-49, that neutralizes the Omicron variant by targeting a conserved epitope and disassembling spike trimers.
bioRxiv · Mar 21, 2022 · PreprintMicrobiology
C. Li, W. Zhan, Z. Yang, C. Tu, Y. Zhu, W. Song, K. Huang, X. Gu, Y. Kong, X. Zhang, M. Zhang, Y. Zhang, Y. Xie, Q. Deng, Z. Chen, , T. Ying
This paper identifies two conserved regions on the Omicron RBD recognized by broadly neutralizing antibodies and develops an inhalable bispecific antibody with broad neutralization and therapeutic efficacy in mice.
bioRxiv · Dec 30, 2021Immunology
Y. Qu, X. Zhang, M. Wang, L. Sun, Y. Jiang, C. Li, W. Wu, Z. Chen, Q. Yin, X. Jiang, Y. Liu, C. Li, J. Li, T. Ying, D. Li, , M. Liang
This study identifies two antibodies, F61 and H121, that neutralize SARS-CoV-2 and its variants, including B.1.1.7 and B.1.351, by targeting distinct epitopes on the RBD.
Virologica Sinica · Jul 5, 2021Peer-reviewedImmunology
Y. Cai, D. Yin, S. Ling, X. Tian, Y. Li, Z. Xu, H. Jiang, X. Zhang, X. Wang, Y. Shi, Y. Zhang, L. Da, S.-c. Tao, Q. Wang, J. Xu, , J. Hong
This study develops a SARS-CoV-2 vaccine candidate using virus simulating particles that induces strong neutralizing immune responses with a single dose.
bioRxiv · May 14, 2020 · PreprintBioengineering
Y. Wu, C. Li, S. Xia, X. Tian, Z. Wang, Y. Kong, C. Gu, R. Zhang, C. Tu, Y. Xie, L. Lu, S. Jiang, T. Ying
This paper develops fully human single-domain antibodies against SARS-CoV-2 and identifies their neutralizing activity and immunogenic profile compared to SARS-CoV and MERS-CoV.
bioRxiv · Mar 30, 2020Microbiology
Q. Wang, E. Michailidis, Y. Yu, Z. Wang, A. M. Hurley, D. A. Oren, C. T. Mayer, A. Gazumyan, Z. Liu, Y. Zhou, T. Schoofs, K.-h. Yao, J. Nieke, J. Wu, Q. Jiang, , M. C. Nussenzweig
The paper identifies broadly neutralizing antibodies against HBV in elite neutralizers and shows that combinations of bNAbs targeting different epitopes are more effective than single bNAbs.
bioRxiv · Mar 4, 2020 · PreprintImmunology
X. Tian, C. Li, A. Huang, S. Xia, S. Lu, Z. Shi, L. Lu, S. Jiang, Z. Yang, Y. Wu, T. Ying
This study shows that the SARS-CoV-specific antibody CR3022 binds strongly to 2019-nCoV RBD with a KD of 6.3 nM, while other antibodies targeting the ACE2 site fail to bind, highlighting the importance of RBD differences for cross-reactivity.
Emerging Microbes & Infections · Feb 17, 2020Peer-reviewedMicrobiology